MyFinsight
Home
Blog
About
Cash and cash
equivalents
$18,411K
(-44.83%↓ Y/Y)
Research and development
tax credit...
$4,413K
(174.95%↑ Y/Y)
Prepaid expenses and
other current assets
$621K
(22.97%↑ Y/Y)
Other tax receivable
$354K
(-35.64%↓ Y/Y)
Total current assets
$23,799K
(-33.95%↓ Y/Y)
Equipment, net
$1,262K
(78.75%↑ Y/Y)
Operating lease right of
use asset
$1,247K
(233.42%↑ Y/Y)
Other assets
$537K
(-5.79%↓ Y/Y)
Total assets
$26,845K
(-28.76%↓ Y/Y)
Total liabilities and
stockholders equity
$26,845K
(-28.76%↓ Y/Y)
Total stockholders
equity
$20,362K
(-29.46%↓ Y/Y)
Total liabilities
$6,483K
(-26.47%↓ Y/Y)
Accumulated deficit
-$215,717K
(-9.33%↓ Y/Y)
Accumulated other
comprehensive loss
-$823K
(-7.86%↓ Y/Y)
Subscription receivable
$814K
Additional paid-in capital
$237,688K
(4.75%↑ Y/Y)
Total current
liabilities
$5,890K
(-31.40%↓ Y/Y)
Long-term operating lease
liability
$593K
(156.71%↑ Y/Y)
Common stock, 0.001 par
value, 200,000,000...
$28K
(3.70%↑ Y/Y)
Accounts payable and
accrued liabilities
$5,053K
(-34.13%↓ Y/Y)
Operating lease, current
liabilities
$812K
(269.09%↑ Y/Y)
Accounts payable and
accrued liabilities ...
$25K
(-86.41%↓ Y/Y)
Back
Back
Balance Sheet
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)
source: myfinsight.com